Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis-Reference-Cited by-同舟云学术

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

Published:2013-01 Issue:1 Volume:68 Page:64-72
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Yeung Howa,Wan Joy,Van Voorhees Abby S.,Callis Duffin Kristina,Krueger Gerald G.,Kalb Robert E.,Weisman Jamie D.,Sperber Brian R.,Brod Bruce A.,Schleicher Stephen M.,Bebo Bruce F.,Shin Daniel B.,Troxel Andrea B.,Gelfand Joel M.

Publisher

Elsevier BV

Subject

Dermatology

Reference40 articles.

1. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening;Kimball;J Am Acad Dermatol,2008

2. Risk of myocardial infarction in patients with psoriasis;Gelfand;JAMA,2006

3. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK;Abuabara;Br J Dermatol,2010

4. Psoriasis and risk of incident myocardial infarction, stroke or transient ischemic attack: an inception cohort study with a nested case-control analysis;Brauchli;Br J Dermatol,2009

5. Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: a nationwide cohort study;Chen;Arthritis Rheum,2012

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis;JAMA Dermatology;2024-08-01

2. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials;Clinical Rheumatology;2024-03-22

3. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT‐1);Journal of the European Academy of Dermatology and Venereology;2024-01-26

4. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan;Dermatology and Therapy;2023-11-29

5. Factors influencing choice of b/ts DMARDs in managing inflammatory arthritis from a patient perspective: a systematic review of global evidence and a patient-based survey from Hong Kong;BMJ Open;2023-10